The genome and the consumer

Publikation: Bidrag til tidsskriftReview (oversigtsartikel)peer review


Consumergenetics has developed so fast that it became possible for consumers to obtain genome risk information based on single nucleotide polymorphisms data of over 250 diseases/conditions for just 99 USD. In November 2013, the American Food and Drug Administration (FDA) ordered the company 23andMe to stop returning health results because they found a lack of scientific evidence of the reposted disease risks. The ethical dilemmas associated with this are reviewed, and the recommendations are described in genome testing. Ethical dilemmas in relation direct-to-consumer testing are discussed.

TidsskriftUgeskrift for laeger
Udgave nummer46
StatusUdgivet - 10 nov. 2014
Udgivet eksterntJa

Bibliografisk note

This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Dyk ned i forskningsemnerne om 'The genome and the consumer'. Sammen danner de et unikt fingeraftryk.